Drugmakers are taking the fight to the Institute for Clinical and Economic Review, touting new data which could be a thorn in the nonprofit’s side.
According to a STAT report, the data suggests seniors suffering from complex diseases could see some difficulty in gaining access to their current treatments if Medicare uses ICER’s findings.
AmericsourceBergen’s Xcenda conducted the research using funding from PhRMA.
Click here to read the full report on STAT. (Paid subscription required)
